

Raising the standard in health care and epidemiology research

Analysis Group Posters and Presentations

ISPOR 2026 | MAY 17-20 | PHILADELPHIA, PENNSYLVANIA

Analysis Group's health care professionals have extensive experience helping clients quantify product value in a dynamic and rapidly changing marketplace.

This year, we are pleased to present an educational symposium, two forums, a podium presentation, and 25 research posters. Please find details below.

All posters will be on display in the Exhibit Hall during their allotted poster session. To view the corresponding abstract and author list for a poster, please click on the **Poster Code** or **Title** below.

Poster Code	Award	Title	Poster Session
<u>EE87</u>		Economic Impact of Delayed Access to Finerenone Due to Formulary Restrictions in Chronic Kidney Disease (CKD) and Type 2 Diabetes (T2D)	Poster Session 1 Monday, May 18 10:30 AM–1:30 PM
<u>EE13</u>		Healthcare Costs Associated with Obesity-Related Conditions and Comorbidities Among U.S. Adults with Overweight or Obesity	Poster Session 1 Monday, May 18 10:30 AM–1:30 PM
<u>EE69</u>		Healthcare Resource Utilization (HCRU) in Pediatric Patients with Hereditary Angioedema (HAE) in the United States: A Matched Study Using Large Insurance Claims	Poster Session 1 Monday, May 18 10:30 AM–1:30 PM
<u>HTA12</u>		Modeling Approaches for Vaccine Indirect Effects in Economic Evaluations: A Scoping Review of Published Reviews and Methodological Guidance	Poster Session 1 Monday, May 18 10:30 AM–1:30 PM
<u>EPH41</u>		Population Effects of Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Canada — A Targeted Literature Review	Poster Session 1 Monday, May 18 10:30 AM–1:30 PM
<u>PT5</u>		Real World Healthcare Resource Utilization and Costs in Metastatic Colorectal Cancer (MCRC) Patients by Line of Therapy in the United States	Poster Session 1 Monday, May 18 10:30 AM–1:30 PM
<u>SA15</u>	Top 5% Finalist	A Multi-Country Retrospective Chart Review of Treatment Patterns and Resource Use in Patients with Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia Undergoing First-Line Consolidation Therapy	Poster Session 2 Monday, May 18 4:00–7:00 PM
<u>CO60</u>		Comparative Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Therapy for Major Depressive Disorder: A Network Meta-Analysis	Poster Session 2 Monday, May 18 4:00–7:00 PM
<u>EE120</u>		Excess Healthcare Costs of Overt Hepatic Encephalopathy (OHE) Relative to Non-OHE Cirrhosis in the United States	Poster Session 2 Monday, May 18 4:00–7:00 PM
<u>EE123</u>		Healthcare Resource Utilization and Economic Burden of Herpes Zoster in Immunocompetent Older Adults in the United States: A Retrospective Cohort Study	Poster Session 2 Monday, May 18 4:00–7:00 PM
<u>EE190</u>	Top 5% Finalist	Real-World (RW) Disease Progression and Healthcare Resource Utilization (HCRU) Among Patients with IgA Nephropathy (IgAN) in the United States (US)	Poster Session 2 Monday, May 18 4:00–7:00 PM

All posters will be on display in the Exhibit Hall during their allotted poster session. To view the corresponding abstract and author list for a poster, please click on the **Poster Code** or **Title** below.

Poster Code	Award	Title	Poster Session
<u>PCR85</u>		Adherence and Persistence in US Real-World New PrEP Users: Cabotegravir vs Emtricitabine/Tenofovir Alafenamide	Poster Session 3 Tuesday, May 19 10:30 AM–1:30 PM
<u>EE229</u>		Caregiver Burden and Socioeconomic Impact of HE and OHE Among Individuals Caring for Patients with Cirrhosis	Poster Session 3 Tuesday, May 19 10:30 AM–1:30 PM
<u>EE258</u>		Increased Healthcare Costs and Resource Utilization Following Progression in Patients with HR+/HER2- Metastatic Breast Cancer Receiving Chemotherapy	Poster Session 3 Tuesday, May 19 10:30 AM–1:30 PM
<u>CO101</u>	Top 5% Finalist	Mean Overall Survival from the Phase 3 MIRASOL Trial of Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in Women with FR?-High Platinum-Resistant Ovarian Cancer (GOG 3045/ENGOT-OV55; NCT04209855)	Poster Session 3 Tuesday, May 19 10:30 AM–1:30 PM
<u>EE412</u>		Budget Impact of Introducing Tapinarof, a New Aryl Hydrocarbon Receptor Agonist, for the Treatment of Atopic Dermatitis in Adult and Pediatric Patients, from a U.S. Medicaid Plan Perspective	Poster Session 4 Tuesday, May 19 4:00–7:00 PM
<u>EPH161</u>		Clinical Characteristics and Treatment Patterns in Cisplatin Eligible Versus Cisplatin Ineligible Muscle Invasive Bladder Cancer Patients with Intent for Resection: A Multicountry Retrospective Chart Review in Europe	Poster Session 4 Tuesday, May 19 4:00–7:00 PM
<u>EE339</u>		Cost of Adverse Event Management in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in the United States	Poster Session 4 Tuesday, May 19 4:00–7:00 PM
<u>EE366</u>		Healthcare Resource Utilization (HRU) and Cost Burden in Non-Metastatic Melanoma in the Modern Treatment Era: A Surveillance, Epidemiology, and End Results (SEER)-Medicare Analysis	Poster Session 4 Tuesday, May 19 4:00–7:00 PM
<u>CO125</u>		Incidence and Mortality Rates of Recurrent Ischemic Strokes Among Medicare Fee-for-Service Beneficiaries in the United States	Poster Session 4 Tuesday, May 19 4:00–7:00 PM
<u>EE332</u>		Incremental Healthcare Costs Associated with Decompensation Events Among Patients with Cirrhosis in the United States	Poster Session 4 Tuesday, May 19 4:00–7:00 PM
<u>RWD124</u>		Treatment and Recurrence Patterns Among Bacillus Calmette Guérin Experienced Patients with Recurrent, Papillary-Only High-Risk Non-Muscle Invasive Bladder Cancer	Poster Session 4 Tuesday, May 19 4:00–7:00 PM

All posters will be on display in the Exhibit Hall during their allotted poster session. To view the corresponding abstract and author list for a poster, please click on the **Poster Code** or **Title** below.

Poster Code	Award	Title	Poster Session
<u>EE424</u>		Healthcare Resource Utilization and Costs of Recurrent Strokes in Medicare Fee-for-Service Beneficiaries in the United States	Poster Session 5 Wednesday, May 20 9:00–11:30 AM
<u>EE462</u>		Treatment Patterns and Healthcare Resource Utilization Among Patients with Localized Prostate Cancer Treated with External Beam Radiation Therapy	Poster Session 5 Wednesday, May 20 9:00–11:30 AM
<u>HSD106</u>		Pathways of Care and Access to Rifaximin Post-Discharge in Medicare-Insured Patients with Overt Hepatic Encephalopathy	Poster Session 5 Wednesday, May 20 9:00–11:30 AM

ISPOR 2026 Analysis Group Presentation

EDUCATIONAL SYMPOSIUM

Tuesday, May 19 | 12:15–1:15 PM

Driving the Next Era of Evidence-Based Medicine through AI, Diverse Data, and Collaboration

Generative AI (GenAI) is transforming evidence-based medicine by enabling novel approaches to the analysis of large-scale, multi-modal, and multi-source data in order to model complex diseases, evaluate treatments, and support more informed decision making. Powered by large language models (LLMs), GenAI enhances the ability to synthesize and interpret diverse data streams – including electronic health records, claims data, disease registries, population-based cohorts, and scientific literature – unlocking deeper insights into disease progression and treatment outcomes. This symposium will explore the frontiers of GenAI in evidence-based medicine, highlighting recent advances, methodological challenges, and practical applications. Presenters will demonstrate how heterogeneous data sources can be enriched and integrated to generate context-specific yet globally relevant insights. The session will also introduce a new real-world evidence research initiative jointly launched by the Harvard T.H. Chan School of Public Health and Analysis Group, focused on advancing precision health through the application of AI to better understand disease pathways, treatment effectiveness, and personalized health. In addition, the symposium will showcase the application of GenAI with digital twin methodologies to simulate the long-term progression of obesity and chronic cardiometabolic diseases, enabling comprehensive assessment of long-term treatment impacts. Collectively, these innovations aim to enable analyses of complex relationships, enhance methodological rigor, and deepen our understanding of disease dynamics. By strengthening the generation and interpretation of real-world evidence, GenAI, together with diverse data ecosystems and strong inter-institutional collaboration, holds significant promise for advancing evidence-based decision making and shaping more effective health care solutions as well as better-informed policy.

Presenters: [Eric Q. Wu](#), Ph.D.; Managing Principal, Analysis Group
[Jimmy Royer](#), Ph.D.; Principal, Analysis Group
Liming Liang, Ph.D.; Professor of Statistical Genetics, Harvard T.H. Chan School of Public Health

ISPOR 2026 Analysis Group Presentation

FORUM

Monday, May 18 | 12:15–1:15 PM

Building Your HEOR Skillset: Core Skills for Advancing Your Career

HEOR individual contributors have the ability to shape perceptions and guide behaviors that are essential for advancing evidence-based decisions. Influencing without authority begins by leveraging networks to build coalitions and align stakeholders around shared goals. Professional success also requires negotiation and persuasion skills to shift perspectives and secure commitment to new ways of thinking. Communicating the value of HEOR in clear and compelling terms, while speaking the language of business, ensures findings resonate with senior leaders and align with organizational priorities. Finally, adaptability allows professionals to remain effective in an environment of constant change, characterized by evolving markets, shifting policies, and competing demands. The new winning combination for HEOR professionals is deep technical expertise paired with a flexible, adaptive mindset that embraces change and drives impact. This session will include an introduction to career-building concepts such as influencing without authority, building and utilizing professional networks to extend reach and credibility, and tailoring influence strategies to target different stakeholders.

Presenters: [Min Yang](#), Ph.D., M.S.; Managing Principal, Analysis Group
David Bruhn, M.B.A., Pharm.D.; Otsuka
Grace E. Fox, Ph.D.; OPEN Health
Haijun Tian, Ph.D.; Eli Lilly

Moderator: Abhijit Gadkari, Novartis

ISPOR 2026 Analysis Group Presentation

FORUM

Monday, May 18 | 12:15–1:15 PM

The Enduring Challenge of Medical Device Identification in Real-World Data: Is Artificial Intelligence Abstraction Ready for Broad Use and Acceptance?

A challenge to generating real-world evidence for medical devices and diagnostics (MDD) is the ability to identify unique MDD products in real-world data. Device specific information, which is not readily available in structured claims data, is typically manually abstracted from unstructured data such as medical charts and physician notes, before being placed into a database for research. This process is lengthy, costly, and can lead to inaccuracies in data capture. Artificial intelligence (AI) methods, such as natural language processing (NLP) and machine learning (ML), have been shown to be a potential solution to this challenge. These methods can lead to fit-for-purpose curated databases that can be used for generating real-world evidence that may meet the needs of regulators, payers, and other healthcare decision makers. AI methods have the potential to identify MDD products within unstructured data and create structured databases that provide information not only on the device of interest, but also on comparators, patient characteristics, and outcomes. The panel will discuss the challenges and opportunities associated with these techniques, including current practice, reliability and validity, and chances of acceptance by regulators and payers. Panel members will discuss use cases from their own experiences. Each speaker will present their perspective for 15 minutes with an additional 15 minutes reserved for audience questions facilitated by the moderator towards the end of the session. Individuals interested in the challenges in extracting unique MDD product and patient data from real world data would benefit from attending.

Presenters: [Jimmy Royer](#), Ph.D.; Analysis Group
Abimbola Williams, M.S., Ph.D.; Boston Scientific
Daniel Caños, M.P.H, Ph.D.; US Food and Drug Administration

Moderator: Lisa Weiss, M.P.H., Ph.D.; Stieber Health Consulting

ISPOR 2026 Analysis Group Presentation

PODIUM PRESENTATION

Monday, May 18 | 1:45–2:45 PM

Consideration of Indirect Effects in National Vaccine Evaluations and Recommendations: A Scoping Review

Guidance from the World Health Organization and other organizations recommends considering indirect effects, such as herd immunity, serotype replacement, and age shift, in vaccine value assessments. This scoping review examines whether and how indirect effects are considered in national vaccine evaluations and recommendations. Although indirect effects are widely acknowledged, their evaluation in national vaccine decision making remains inconsistent and methodologically underdeveloped. Clearer guidance on assessing indirect effects could improve cross-country comparability and support evidence generation.

Presenter: Min Huang, Ph.D.; Merck

Coauthors: [Weiguang Xue](#), M.Sc.; Vice President, Analysis Group
[Yanwen Xie](#), M.Sc.; Manager, Analysis Group
Jack Eales, M.Sc.; Senior Analyst, Analysis Group
Walter A. Orenstein, M.D.; School of Medicine, Emory University
Zinan Yi, Ph.D.; Merck
Rachel J. Oidtman, Ph.D.; Merck
Elamin Elbasha, B.Sc., M.A., Ph.D.; Merck
Michael Drummond, M.Com., D.Phil.; Centre for Health Economics, University of York